Dancann Pharma

Overview
News
Cannabis?
Product stageSegments
Expansion
?
Extractors and infusers
?

DanCann Pharma A/S is a Danish biopharmaceutical company powered by cannabinoids, founded in 2018. The company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids across various disease areas. DanCann Pharma is a licensed production and distribution company based in Denmark.

The company utilizes a core cultivation technique called vertical aeroponics systems, initially developed by NASA. This technique enables DanCann Pharma to regulate factors like temperature, humidity, light, and irrigation, ensuring consistent quality and strength of the cannabinoids produced. The company strives to maintain the high quality and safety standards associated with the traditional pharmaceutical industry.

DanCann Pharma's product offerings target indications such as multiple sclerosis, chronic pain, spinal cord injury, and nausea caused by chemotherapy. The company's primary target group is patients undergoing treatment for chronic pain.

In August 2022, DanCann Pharma signed a supply agreement with WEECO Pharma GmbH for the German market, worth approximately DKK 40 million from 2023 to 2025. Under this agreement, DanCann Pharma will sell and export flower products with a focus on THC genetics and potential candidates to WEECO Pharma.

In December 2022, the company received EU-GMP accreditation for its manufacturing facility, biotech Pharm 1, enabling it to officially participate in the Danish medical cannabis pilot program.


Sources

Disclaimer: This company profile has been generated using data obtained through automated web searches and advanced generative AI technology. While we strive to ensure the accuracy and reliability of our sources, auto-generated information could be outdated or inaccurate and should be verified independently.
HQ location:
Rugvænget 5 DK-6823 Ansager Ansager DNK
Founded year:
2018
Employees:
11-50
IPO status:
Public
Total funding:
USD 5.1 mn
Last Funding:
USD 995.3 k (Post IPO Equity; Jun 2024)
Last valuation:
-
Key competitors
Filter by the segments to which the disruptor belongs
All Segmentsexpand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.